Abstract Coronavirus Disease 2019 (COVID-19) has been the most severe public health
challenge in this century. Two years after its emergence, the rapid development and …

Background Vaccines are critical cost-effective tools to control the coronavirus disease 2019
(COVID-19) pandemic. However, the emergence of variants of the severe acute respiratory …

Background It was urgent and necessary to synthesize the evidence for vaccine
effectiveness (VE) against SARS-CoV-2 variants of concern (VOC). We conducted a …

The effectiveness of the BNT162b2 and ChAdOx1 vaccines against new severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) infections requires continuous re …

Background We aimed to assess the settings and activities associated with SARS-CoV-2
infection in the context of B. 1.617. 2 (Delta) variant circulation in France, as well as the …

Background The incubation period of SARS-CoV-2 has been estimated for the known
variants of concern. However, differences in study designs and settings make comparing …

Since the COVID-19 pandemic first began in December 2019, the severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) virus has continuously evolved with many variants …

Severe acute respiratorysyndrome coronavirus‐2 (SARS‐CoV‐2) pandemic spread rapidly
and this scenario is concerning worldwide, presenting more than 590 million coronavirus …

The ongoing COVID-19 pandemic caused by severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) has become a global threat. Despite strict control measures …

Timely evaluation of the protective effects of Coronavirus Disease 2019 (COVID-19)
vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants …